| Size | Price | |
|---|---|---|
| 1mg | ||
| Other Sizes |
| Targets |
Mating Factor α (1-6) targets the Ste2 receptor, a G protein-coupled receptor expressed on a-mating type *S. cerevisiae* cells. Binding of the peptide to Ste2 activates a MAP kinase signaling cascade that leads to cell cycle arrest and inhibition of DNA synthesis. The (1-6) fragment contains the N-terminal region of the full-length mating factor and may act as a partial agonist or antagonist at Ste2. It is used to study the structural requirements for mating factor activity and to develop yeast-based assays for pheromone signaling.
|
|---|---|
| ln Vitro |
In vitro, Mating Factor α (1-6) inhibits the initiation of DNA synthesis in a-mating type yeast cells, as measured by [³H]-thymidine incorporation or by cell cycle analysis. The peptide is soluble in water and physiological buffers and is stable at −20°C as a lyophilized powder. It is used in yeast growth inhibition assays (halo assays) and for studying pheromone signaling. Detailed potency data for this fragment are limited in the literature.
|
| ln Vivo |
In vivo, Mating Factor α (1-6) is used in yeast-based assays rather than animal studies. It can be added to yeast cultures to inhibit DNA synthesis and induce cell cycle arrest. The peptide is used to study yeast pheromone signaling and for screening mating pathway inhibitors. No animal studies are applicable.
|
| Enzyme Assay |
For non-cellular assays, Mating Factor α (1-6) is used in receptor binding assays. Membranes from Ste2-expressing yeast cells are incubated with [³H]-α-mating factor in the presence or absence of Mating Factor α (1-6). Bound radioactivity is separated by filtration and measured.
|
| Cell Assay |
For cell-based assays, a-mating type yeast cells are grown in YPD medium to mid-logarithmic phase. Mating Factor α (1-6) is added at concentrations ranging from 0.1 to 100 µM, and DNA synthesis is measured by [³H]-thymidine incorporation. Cell cycle arrest is assessed by flow cytometry or microscopy.
|
| Animal Protocol |
In vivo animal experiments with Mating Factor α (1-6) are not applicable. The peptide is used in yeast-based assays only. No animal procedures are required.
|
| References |
| Molecular Formula |
C45H59N11O8
|
|---|---|
| Molecular Weight |
882.018860000001
|
| Exact Mass |
881.455
|
| CAS # |
65418-88-4
|
| PubChem CID |
90474511
|
| Sequence |
WHWLQL
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.32g/cm3
|
| Boiling Point |
1395.3ºC at 760 mmHg
|
| Flash Point |
797.6ºC
|
| Index of Refraction |
1.636
|
| LogP |
4.948
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
24
|
| Heavy Atom Count |
64
|
| Complexity |
1620
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
CC(C[C@H](NC([C@@H](NC([C@@H](NC([C@@H](N)CC1=CNC2=CC=CC=C12)=O)CC3=CN=CN3)=O)CC4=CNC5=CC=CC=C45)=O)C(N[C@H](C(N[C@H](C(O)=O)CC(C)C)=O)CCC(N)=O)=O)C
|
| InChi Key |
PBLMMVDDGREFKH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C45H59N11O8/c1-24(2)15-35(42(60)52-34(13-14-39(47)57)41(59)56-38(45(63)64)16-25(3)4)54-43(61)36(18-27-21-50-33-12-8-6-10-30(27)33)55-44(62)37(19-28-22-48-23-51-28)53-40(58)31(46)17-26-20-49-32-11-7-5-9-29(26)32/h5-12,20-25,31,34-38,49-50H,13-19,46H2,1-4H3,(H2,47,57)(H,48,51)(H,52,60)(H,53,58)(H,54,61)(H,55,62)(H,56,59)(H,63,64)
|
| Chemical Name |
2-[[5-amino-2-[[2-[[2-[[2-[[2-amino-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1338 mL | 5.6688 mL | 11.3376 mL | |
| 5 mM | 0.2268 mL | 1.1338 mL | 2.2675 mL | |
| 10 mM | 0.1134 mL | 0.5669 mL | 1.1338 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
